Literature DB >> 17446827

Diagnosis of advanced cancer among elderly Medicare and Medicaid patients.

Cathy J Bradley1, Charles W Given, Bassam Dahman, Zhehui Luo, Beth A Virnig.   

Abstract

BACKGROUND: Medicaid is implicated in late-stage cancer diagnoses, which is the primary indicator of a poor prognosis.
OBJECTIVE: We examined Medicaid enrollment and cancer diagnosis in patients ages 66 years and older. Medicaid enrollment was defined as enrolled 12+ months before diagnosis, enrolled <12 months before diagnosis, and enrolled after diagnosis.
SUBJECTS: Medicaid and Medicare administrative data were merged with the Michigan Tumor Registry to extract a sample of 46,109 patients with a first primary diagnosis of prostate, lung, breast, or colorectal cancer between 1997 and 2000. Measures were: (1) diagnosed during the same month as death; (2) invasive, but unknown stage; and (3) regional or distant stage disease.
RESULTS: : Patients enrolled in Medicaid <12 months before diagnosis were at greater risk of breast (odds ratio [OR] = 2.70; 95% confidence interval [95% CI] = 1.22-5.99) and lung (OR = 2.18; 95% CI = 1.45-3.29) cancer diagnosis in the month of death than Medicare only patients. Similarly, patients with a history of Medicaid enrollment had a high risk of diagnosis with invasive, but unknown breast, lung, and prostate cancer stage. Patients enrolled in Medicaid following diagnosis had a higher risk of late stage colorectal (OR = 1.30; 95% CI = 1.01-1.67), breast (OR = 2.12; 95% CI = 1.60-2.82), and lung (OR = 1.33; 95% CI = 1.02-1.75) cancer relative to Medicare only patients.
CONCLUSIONS: There is a preponderance of cancer diagnosis at death and cancer diagnosis with invasive but unknown stage in the Medicaid population, but the appropriateness of these diagnoses is unclear. Late-stage cancer tends to precipitate Medicaid enrollment.

Entities:  

Mesh:

Year:  2007        PMID: 17446827     DOI: 10.1097/01.mlr.0000256970.19359.2a

Source DB:  PubMed          Journal:  Med Care        ISSN: 0025-7079            Impact factor:   2.983


  9 in total

1.  Effect of the Breast and Ccervical Cancer Ttreatment Act on access to screening and treatment in Oklahoma.

Authors:  Janis E Campbell; David M Thompson; Anne E Pate
Journal:  J Okla State Med Assoc       Date:  2014-01

2.  Comorbidities, functional limitations, and geriatric syndromes in relation to treatment and survival patterns among elders with colorectal cancer.

Authors:  Siran M Koroukian; Fang Xu; Paul M Bakaki; Mireya Diaz-Insua; Tanyanika Phillips Towe; Cynthia Owusu
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2009-12-16       Impact factor: 6.053

3.  Variation in Intensity and Costs of Care by Payer and Race for Patients Dying of Cancer in Texas: An Analysis of Registry-linked Medicaid, Medicare, and Dually Eligible Claims Data.

Authors:  B Ashleigh Guadagnolo; Kai-Ping Liao; Sharon H Giordano; Linda S Elting; Ya-Chen T Shih
Journal:  Med Care       Date:  2015-07       Impact factor: 2.983

4.  Cancer outcomes in low-income elders: is there an advantage to being on Medicaid?

Authors:  Siran M Koroukian; Paul M Bakaki; Cynthia Owusu; Craig C Earle; Gregory S Cooper
Journal:  Medicare Medicaid Res Rev       Date:  2012-07-30

5.  Ability of Medicare claims data to identify nursing home patients: a validation study.

Authors:  Siran M Koroukian; Fang Xu; Patrick Murray
Journal:  Med Care       Date:  2008-11       Impact factor: 2.983

6.  Surveillance mammography for Medicaid/Medicare breast cancer patients.

Authors:  Patricia Carcaise-Edinboro; Cathy J Bradley; Bassam Dahman
Journal:  J Cancer Surviv       Date:  2009-12-20       Impact factor: 4.442

7.  The utility of the state buy-in variable in the Medicare denominator file to identify dually eligible Medicare-Medicaid beneficiaries: a validation study.

Authors:  Siran M Koroukian; Bassam Dahman; Glenn Copeland; Cathy J Bradley
Journal:  Health Serv Res       Date:  2009-10-15       Impact factor: 3.402

8.  Cancer incidence in elderly Medicare and dually eligible beneficiaries.

Authors:  Cathy J Bradley; Zhehui Luo; Charles W Given
Journal:  Health Serv Res       Date:  2008-05-12       Impact factor: 3.402

9.  Cancer Treatment for Dual Eligibles: What Are the Costs and Who Pays?

Authors:  Susan G Haber; Florence K L Tangka; Lisa C Richardson; Susan A Sabatino; David Howard
Journal:  Am J Cancer Sci       Date:  2013-04-29
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.